Mycophenolate mofetil and atherosclerosis - Results of animal and human studies

被引:22
作者
Gibson, William Thomas [1 ]
Hayden, Michael Reuben [1 ]
机构
[1] Univ British Columbia, Child & Family Res Inst, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada
来源
AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH | 2007年 / 1110卷
关键词
atherosclerosis; coronary allograft vasculopathy; immunosuppressants; mycophenolate mofetil; mycophenolic acid; transplantation;
D O I
10.1196/annals.1423.023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immunosuppressive agent mycophenolate mofetil (MMF) has beneficial effects in cardiac transplant patients beyond the suppression of tissue rejection. Patients with regimens containing MMF experience diminished intimal thickening and cardiac allograft vasculopathy compared to patients treated with azathioprine. Studies have shown that diet-induced atherosclerosis (a related vasculopathy) is a chronic inflammatory process, and so MMF has also been used to reduce atherosclerosis in a rabbit model of hyperlipidemia. These data hold out the intriguing possibility that MMF might be a viable primary or secondary preventive agent in people at significant risk for atherosclerosis.
引用
收藏
页码:209 / 221
页数:13
相关论文
共 50 条
[31]   Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion [J].
Lui, SL ;
Ramassar, V ;
Urmson, J ;
Halloran, PF .
TRANSPLANT IMMUNOLOGY, 1998, 6 (01) :23-32
[32]  
Manzi S, 1997, AM J EPIDEMIOL, V145, P408
[33]   EFFECT OF MYCOPHENOLATE MOFETIL (RS-61443) ON CYTOKINE PRODUCTION - INHIBITION OF SUPERANTIGEN-INDUCED CYTOKINES [J].
NAGY, SE ;
ANDERSSON, JP ;
ANDERSSON, UG .
IMMUNOPHARMACOLOGY, 1993, 26 (01) :11-20
[34]   INHIBITION OF CHRONIC VASCULAR REJECTION IN PRIMATE CARDIAC XENOGRAFTS USING MYCOPHENOLATE MOFETIL [J].
OHAIR, DP ;
MCMANUS, RP ;
KOMOROWSKI, R .
ANNALS OF THORACIC SURGERY, 1994, 58 (05) :1311-1315
[35]   Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: Influence on inflammation and progression of intimal hyperplasia [J].
Pethig, K ;
Heublein, B ;
Wahlers, T ;
Dannenberg, O ;
Oppelt, P ;
Haverich, A .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2004, 23 (01) :61-66
[36]  
Raisanen-Sokolowski A, 1995, Transpl Immunol, V3, P342, DOI 10.1016/0966-3274(95)80021-2
[37]   Reduction of ICAM-1 and LFA-1-positive leukocytes in the perivascular space of arteries under mycophenolate mofetil therapy reduces rat heart transplant vasculopathy [J].
Richter, M ;
Zahn, S ;
Richter, H ;
Mohr, FW ;
Olbrich, HG .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2004, 23 (12) :1405-1413
[38]   Mycophenolate mofetil significantly reduces leukocyte graft infiltration after heterotopic cardiac transplantation in a rat model: Comparative study with cyclosporine and FK 506 [J].
Richter, MHC ;
Zahn, S ;
Kraus, M ;
Mohr, FW ;
Olbrich, HG .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2003, 22 (10) :1107-1116
[39]   Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus [J].
Roman, MJ ;
Shanker, B ;
Davis, A ;
Lockshin, MD ;
Sammaritano, L ;
Simantov, R ;
Crow, MK ;
Schwartz, JE ;
Paget, SA ;
Devereux, RB ;
Salmon, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2399-2406
[40]   Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit [J].
Romero, F ;
Rodríguez-Iturbe, B ;
Pons, H ;
Parra, G ;
Quiroz, Y ;
Rincón, J ;
González, L .
ATHEROSCLEROSIS, 2000, 152 (01) :127-133